We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Capturing the Physiologic Mechanisms of Early Stage Cancer with 3D Multi-Photon Fluorescence Microscopy

By Biotechdaily staff writers
Posted on 04 Dec 2007
Biomedical engineers have captured three-dimensional (3D) images revealing microscopic changes to the inner processes of cells that occur at the earliest stages of cancer, suggesting a possible new way of disease detection. More...


Researchers from Duke University's Pratt School of Engineering (Durham, NC, USA) reported that their findings in animals also suggest that the so-called multi-photon fluorescence microscopy--a technique that had generally been limited to the basic science laboratory--might also find a use in the clinic.

"We were able to capture physiological information about tissue in a living and breathing animal, in three dimensions,” said Dr. Nirmala Ramanujam, an associate professor of biomedical engineering. "We peered into individual cells in a very non-invasive way to see how things change as early cancer progresses.” The ability to examine live tissue is critical because tissue removal erases metabolic features that are hallmarks of cancer, added Dr. Melissa Skala, a former doctoral student in Dr. Ramanujam's laboratory.

Drs. Ramanujam and Skala's findings were published online November 19, 2007, in an early edition of the journal Proceedings of the U.S. National Academy of Sciences (PNAS). The microscope used in the new study is just one of several light-based, or photonic devices Dr. Ramanujam's group is investigating for their potential to identify biomarkers indicative of cancer.

Multi-photon microscopy utilizes pulses of laser light to excite molecules with the natural capacity to give off light, or fluoresce. In the new study, the researchers used the imaging technique to examine cell structure in fine detail and to quantify the relative amounts of two important metabolic coenzymes based on their fluorescence intensity. That ratio provides information about a cell's metabolic rate and oxygen supply, the researchers explained.

They also measured the coenzymes' "fluorescence lifetime”--the amount of time before they give off light--giving additional, though less well understood, insight into the metabolic environment within cells, according to Dr. Ramanujam.

The researchers captured images of cells in the cheek pouches of almost two dozen hamsters, including several cancer-free animals and others at various stages of early oral cancer. Those images revealed significant differences in the structural and metabolic characteristics of early cancer versus non-cancer. Their studies suggested that the fluorescence lifetime is the best indicator of pre-cancer state, making it a promising new way of disease detection.

"There is always a need to identify new biomarkers for cancer or for monitoring the response to cancer therapy,” Dr. Ramanujam said. "Our goal is to leverage biophotonics to compare well-established markers of cancer to ones that have yet to be exploited.”

While existing multiphoton microscopes themselves could be evaluated in the clinic, Dr. Ramanujam reported that her team's goal would be to design and construct simple devices that are customized for medical use.


Related Links:
Duke University's Pratt School of Engineering

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.